Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

It's not just weightlifting and treadmills anymore. These days, group fitness classes like line-dancing are bringing lots of ...

This was the stock's third consecutive day of gains.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

While maintaining a Neutral rating on Alphabet, the broker argues that it "would see GOOGL as the top mega cap pick if it ...

Beer and wine lovers rejoice: The VRTX Restaurant and Bar — a community-driven restaurant offering craft beer and local ...

Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.

Vertex Pharmaceuticals secured EU approval for ALYFTREK, a next-gen cystic fibrosis therapy boasting a better efficacy ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...